香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 建議變更募集資金用途 為提高募集資金使用效率，經董事會審議通過，以將全球發售募集資金淨額中 劃撥的143.8百萬港元的擬定用途作出調整，由擬用於在為位於遼寧省葫蘆島 市的生產工廠的生產活動提供部分資金、在烏茲別克斯坦及印度尼西亞建設 海外生產工廠、實施營銷計劃、償還部分銀行貸款與一般營運資金變更為用於 廣東省茂名市設立水泥助磨劑與混凝土助磨劑生產工廠項目（「茂名項目」）（「建 議變更」）。 根據本公司章程細則，變更未動用募集資金淨額的用途須取得股東批准。因此， 建議變更需待股東於本公司股東會上以普通决議案方式批准後方可作實。 Anhui Conch Material Technology Co., Ltd. 安徽海螺材料科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：02560） 建議變更募集資金用途 茲提述(i)安徽海螺材料科技股份有限公司（「本公司」）日期為二零二四年十二月 ...

Core Viewpoint - Mingke Technology (001319.SZ) plans to change part of its fundraising usage to acquire a 53.2530% stake in Anhui Shuangjun Intelligent Technology Co., Ltd for 143.7831 million RMB, with 90 million RMB from raised funds and 53.7831 million RMB from its own funds [1][2]. Group 1: Fundraising and Acquisition Details - The acquisition has been approved by the company's board and will be submitted for shareholder approval [1]. - The transaction does not constitute a related party transaction or a major asset restructuring as per regulations [1]. - After the acquisition, Anhui Shuangjun will become a subsidiary of Mingke Technology and will be included in the consolidated financial statements [1]. Group 2: Financial Performance of Anhui Shuangjun - Anhui Shuangjun is projected to achieve revenues of 240.1083 million RMB in 2024 and 319.2587 million RMB in 2025, with net profits of 29.9458 million RMB and 28.1193 million RMB respectively [2][3]. - The company's total equity value is assessed at 277 million RMB, reflecting a 96.10% increase over its book net assets of 141 million RMB [3]. Group 3: Previous Acquisitions and Strategic Adjustments - This is not the first acquisition by Mingke Technology; it previously acquired 80% of Hiroshima Technology (Nanjing) Automotive Parts Co., Ltd for 66.717 million RMB, which was completed in November 2025 [4]. - The company aims to optimize the use of raised funds and enhance its capabilities in key assembly processes and system solutions through this acquisition [4].

Core Viewpoint - The company has decided to suspend the research and application of the African Swine Fever freeze-dried inactivated vaccine due to significant uncertainties and challenges in the project, which will also lead to the recognition of goodwill impairment [14][19][21]. Group 1: Suspension of Vaccine Development - The board of directors unanimously approved the suspension of the African Swine Fever vaccine development project [14][20]. - The decision was made after recognizing the high technical difficulty and long regulatory approval cycles associated with the vaccine development [19][21]. - The suspension is not expected to have a significant adverse impact on the company's existing business operations [21]. Group 2: Goodwill Impairment - The company plans to recognize a goodwill impairment of approximately 17,499.47 million yuan due to the suspension of the vaccine project [30]. - This impairment is expected to reduce the net profit attributable to shareholders by about 14,981.30 million yuan for the fiscal year 2025 [30]. - The board believes that this impairment aligns with accounting standards and reflects the company's asset status more accurately [30]. Group 3: Financing Lease Business - The company approved a financing lease agreement for its subsidiary, aiming to optimize financing structure and enhance asset liquidity [33][49]. - The total financing amount is expected to be up to 14,100 million yuan, with a lease term of 30 months [33][49]. - The company will provide a guarantee for the financing lease based on its ownership percentage in the subsidiary [34][49]. Group 4: Change of Fundraising Purpose - The company has decided to change the use of unutilized fundraising from the "Animal Vaccine Production Base Construction Project" to two new projects: "Energy System and Fermentation System Optimization Project" and "3,500 tons/year Powder and Granule Automated Closed Production Line Project" [52][55]. - The total amount to be reallocated is 9,254.83 million yuan, which is approximately 11.54% of the actual net fundraising amount [53][55]. - This change is aimed at improving the efficiency of fundraising use and aligning with the company's operational needs [52][55].

Group 1 - The company is holding its first extraordinary general meeting of shareholders on January 30, 2026, to discuss adjustments to the use of raised funds [2][5] - The board of directors approved a proposal to adjust the use of raised funds, reducing the investment in the nutrition health raw material production base project from 206.29 million to 107.80 million yuan, reallocating the difference to new projects [2][8] - The company decided to cancel the changes related to the nutrition health raw material production base project, ensuring that all raised funds will still be directed to the original investment project [3][9] Group 2 - The adjusted allocation of raised funds will account for 20.76% of the company's net raised funds, and the changes do not constitute a related party transaction [4][11] - The board agreed to submit the adjusted proposal to the extraordinary general meeting for approval, while the original proposal will not be submitted again [4][14] - The meeting will take place at the company's office in Shanghai, with provisions for online voting through the Shanghai Stock Exchange's system [5][6]

Meeting Overview - The third board meeting of Jiangsu Huayang Intelligent Equipment Co., Ltd. was held on January 16, 2026, with all 9 directors present [2][5] - The meeting was chaired by Chairman Xu Yunchu and complied with relevant laws and regulations [2] Resolutions Passed - The board approved the proposal to change the use of part of the raised funds, reallocating CNY 81.3122 million from the "Intelligent Precision Injection Medical Device Industrialization Project" to the "Precision Micro Motor and Application Products Intelligent Manufacturing Base Construction Project" [2][14] - The adjustment aims to enhance the efficiency of fund utilization while ensuring the normal operation of the projects [14][25] Fundraising Details - The company raised a total of CNY 399.7307 million from its initial public offering, with a net amount of CNY 345.1581 million after deducting issuance costs [14][16] - The funds are managed in a special account with a tripartite supervision agreement in place [15] Project Investment Overview - The "Intelligent Precision Injection Medical Device Industrialization Project" has a total investment of CNY 310.4175 million, with CNY 210.915 million from raised funds [18] - The "Precision Micro Motor and Application Products Intelligent Manufacturing Base Construction Project" has a total investment of CNY 138.855 million, with CNY 134.2431 million from raised funds [18] Market Analysis - The adjustment in fund allocation is based on the current market trends and the company's strategic planning, aiming to optimize fund distribution and capture market opportunities [22][30] - The demand for precision micro motors is expected to grow significantly due to trends in smart home appliances and the expansion of the central air conditioning market [22][28] Future Shareholder Meeting - A temporary shareholder meeting is scheduled for February 6, 2026, to discuss the approved resolutions [11][37] - The meeting will include provisions for both on-site and online voting [39][41]

Meeting Overview - The first temporary shareholders' meeting of Beijing Qianfang Technology Co., Ltd. was held on January 12, 2026, with both on-site and online voting options available [3][5][11] - The meeting was attended by 602 participants, representing 394,706,755 shares, which is 25.0335% of the total voting shares [10] Voting Results - The proposal to change the use of part of the raised funds was approved with 99.8440% of the votes in favor [11] - The proposal for the 2025 interim cash dividend plan was also approved with 99.8568% of the votes in favor [13] Legal Compliance - The meeting was conducted in accordance with relevant laws and regulations, as confirmed by the legal opinion from Beijing Tianyuan Law Firm [14]

Core Viewpoint - The company announced a board meeting on January 6, 2026, to review the proposal for changing the use of part of the raised funds and extending the timeline for the project [1] Group 1: Fund Allocation Changes - The company plans to allocate the unused funds of 38.346 million yuan from the "30,000 tons/year incineration disposal project" to the second phase of the same project [1] - The expected usable status date for the funds has been adjusted from March 31, 2026, to September 30, 2026 [1] Group 2: Project Termination and Reallocation - The company has terminated two projects, including the "physical dismantling and expansion of refrigerator lines," and will redistribute the remaining funds [1] - The changes do not constitute a major asset restructuring and are subject to shareholder approval, with no objections from the sponsor institution [1]

Core Viewpoint - Daoshi Technology (300409.SZ) announced a strategic reallocation of funds from its ternary precursor project and recycling research institute project to a new copper smelting project in the Democratic Republic of Congo [1] Group 1: Financial Overview - As of November 30, 2025, the ternary precursor project has accumulated an investment of RMB 326.77 million, with an uninvested amount of RMB 1.13 billion, including interest income and investment returns [1] - The recycling research institute project has an uninvested amount of RMB 104.03 million, also including interest income and investment returns [1] Group 2: Strategic Fund Reallocation - The company plans to transfer RMB 1 billion from the uninvested funds of the ternary precursor project and RMB 104.03 million from the recycling research institute project to the "30kt cathode copper hydrometallurgy plant project" in the Democratic Republic of Congo [1]

Group 1 - The company, Qianfang Technology (002373.SZ), announced the approval of a proposal to change the use of part of the raised funds at the 14th meeting of the sixth board of directors [1] - The company will terminate the implementation of the 2020 non-public offering project for specific objects, titled "R&D Upgrade and Industrialization of Next-Generation Smart Transportation System Products and Solutions" [1] - The remaining raised funds amount to 955.7047 million yuan, which includes financial income and interest of 41.6048 million yuan [1] Group 2 - The purpose of the remaining funds will be changed to implement a new investment project titled "R&D and Industrialization of Key Technologies for Unmanned Logistics" [1] - The sponsor institution, Guotai Junan Securities Co., Ltd., has issued a consent verification opinion on this matter [1]

Group 1 - The company held its fifth extraordinary general meeting on December 22, 2025, with no resolutions being rejected [2] - The meeting was legally convened and conducted according to the Company Law and the company's articles of association, with all procedures being valid [5][7] - The board of directors approved a proposal to change the use of part of the raised funds [4] Group 2 - The board of directors' second meeting was also held on December 22, 2025, with all directors present, and the meeting was legally valid [7] - The board approved a proposal to cease operations of subsidiaries related to the photovoltaic encapsulation film project due to market changes and to enhance profitability [8][9] - A proposal to convene the first extraordinary general meeting of 2026 was also approved [10] Group 3 - The company has established four photovoltaic encapsulation film projects, but three of them have been terminated [13] - The decision to stop the photovoltaic encapsulation film project is based on ongoing low prices in the photovoltaic component market and insufficient demand [14] - The company plans to repurpose or sell the facilities and equipment used for the ceased project to optimize resource utilization [14] Group 4 - As of November 30, 2025, the raised funds for the photovoltaic encapsulation film project have been managed according to regulations, with some funds allocated for working capital [16] - The photovoltaic encapsulation film project contributed 48% of total revenue in 2024 and is expected to have a negative net profit of approximately 240 million yuan in 2024 [17] - The cessation of this project is anticipated to improve the company's overall profitability and will not affect other business segments [17]